Your browser doesn't support javascript.
loading
Omicron BA.4/5 Neutralization and T-Cell Responses in Organ Transplant Recipients After Booster Messenger RNA Vaccine: A Multicenter Cohort Study.
Ferreira, Victor H; Ierullo, Matthew; Mavandadnejad, Faranak; Kurtesi, Alexandra; Hu, Queenie; Hardy, W Rod; Hall, Victoria G; Pinzon, Natalia; Yotis, Demitra; Gingras, Anne-Claude; Belga, Sara; Shalhoub, Sarah; Hébert, Marie-Josée; Humar, Atul; Kabbani, Dima; Kumar, Deepali.
Afiliação
  • Ferreira VH; Department of Medicine, Ajmera Transplant Centre, University Health Network, Toronto, Ontario, Canada.
  • Ierullo M; Department of Medicine, Ajmera Transplant Centre, University Health Network, Toronto, Ontario, Canada.
  • Mavandadnejad F; Department of Medicine, Ajmera Transplant Centre, University Health Network, Toronto, Ontario, Canada.
  • Kurtesi A; Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health, Toronto, Ontario, Canada.
  • Hu Q; Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health, Toronto, Ontario, Canada.
  • Hardy WR; Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health, Toronto, Ontario, Canada.
  • Hall VG; Department of Medicine, Ajmera Transplant Centre, University Health Network, Toronto, Ontario, Canada.
  • Pinzon N; Department of Medicine, Ajmera Transplant Centre, University Health Network, Toronto, Ontario, Canada.
  • Yotis D; Canadian Donation and Transplantation Research Program, Edmonton, Alberta, Canada.
  • Gingras AC; Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health, Toronto, Ontario, Canada.
  • Belga S; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
  • Shalhoub S; Division of Infectious Diseases, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • Hébert MJ; Department of Medicine, London Health Sciences Centre, London, Ontario, Canada.
  • Humar A; Department of Medicine, Centre Hôspitalier de L'Université de Montréal, Montréal, Quebec, Canada.
  • Kabbani D; Department of Medicine, Ajmera Transplant Centre, University Health Network, Toronto, Ontario, Canada.
  • Kumar D; Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Clin Infect Dis ; 77(2): 229-236, 2023 07 26.
Article em En | MEDLINE | ID: mdl-36975097
BACKGROUND: In solid organ transplant (SOT) recipients, the primary vaccination series against Coronavirus Disease 2019 is 3 doses followed by boosters. We determined whether a fourth dose booster induced Omicron BA.4/5 neutralizing antibodies (nAbs) and T cells in a large multicenter cohort study. METHODS: Serum was collected 4-6 weeks post-third and post-fourth doses of messenger RNA vaccine in 222 SOT recipients. nAbs were measured using a pseudovirus neutralization assay that targeted the Omicron BA.4/5 spike protein. A subset underwent T-cell testing. RESULTS: The median age of the cohort was 63 years (interquartile range [IQR], 50-68) with 61.7% men. BA.4/5 nAb detection increased from 26.6% (59 of 222) post-third dose to 53.6% (119 of 222) post-fourth dose (P < .0001). In patients with breakthrough infection prior to the fourth dose (n = 27), nAbs were detected in 77.8% and median nAb titers were significantly higher compared with those with 4 vaccine doses alone (P < .0001). Factors associated with a low BA.4/5 neutralization response after the fourth dose were older age (odds ratio [OR], 0.96; 95% confidence interval [CI], .94-.99), mycophenolate use (OR, 0.39; 95% CI, .20-.77) and prednisone use (OR, 0.34; 95% CI, .18-.63), and vaccine type (OR, 0.72; 95% CI, .51-.99), while breakthrough infection prior to the fourth dose (OR, 3.6; 95% CI, 1.3-9.9) was associated with a greater nAb response. Polyfunctional BA.4/5-specific CD4+ T cells significantly increased after 4 doses and were identified in 76.9% of patients at a median frequency of 213/106 cells (IQR, 98-650). CONCLUSIONS: In summary, a booster significantly increases BA.4/5-specific neutralization and polyfunctional CD4+ T-cell responses, suggesting protection from severe disease even with new Omicron variants. However, SOT recipients who are older and on mycophenolate and prednisone need additional preventative strategies.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Órgãos / COVID-19 Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged Idioma: En Revista: Clin Infect Dis Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Canadá

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Órgãos / COVID-19 Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged Idioma: En Revista: Clin Infect Dis Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Canadá